Novo Nordisk A/S – Share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission’s regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk has repurchased B shares for an amount of DKK
2.4 billion in the period from 10 August 2009 to 18 December 2009. Consequently,
the programme was concluded on 18 December 2009.

Since the announcement as of 14 December 2009, the following transactions have
been made under the programme:




                                  Average     Transaction value,
                    Number of
                               purchase price         DKK
                      shares

 Accumulated, last

 announcement        7,031,599                     2,269,401,725

 14 December 2009       73,000       334.9700         24,452,810

 15 December 2009       75,000       332.3000         24,922,500

 16 December 2009       80,000       331.9000         26,552,000

 17 December 2009       82,335       335.4910         27,622,651

 18 December 2009       79,833       338.8100         27,048,219

 Accumulated under

 the programme       7,421,767                     2,399,999,906



With the transactions stated above, Novo Nordisk owns a total of 32,137,945
treasury shares, corresponding to 5.2% of the share capital. The total amount of
shares in the company is 620,000,000 including treasury shares.



Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81
countries, and markets its products in 179 countries. Novo Nordisk’s B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol ‘NVO’. For more information,
visit novonordisk.com.

 Further information:


 Media:                                  Investors:



 Elin K Hansen                           Mads Veggerby Lausten

 Tel: (+45) 4442 3450                    Tel: (+45) 4443 7919

 ekh@novonordisk.com                     mlau@novonordisk.com
 <mailto:ekh@novonordisk.com>            <mailto:mlau@novonordisk.com>



                                         Kasper Roseeuw Poulsen

                                         Tel: (+45) 4442 4471

                                         krop@novonordisk.com
                                         <mailto:krop@novonordisk.com>



 In North America:                       In North America:

 Sean Clements                           Hans Rommer

 Tel: (+1) 609 514 8316                  Tel: (+1) 609 919 7937

 secl@novonordisk.com                    hrmm@novonordisk.com
 <mailto:secl@novonordisk.com>           <mailto:hrmm@novonordisk.com>



Company Announcement no 74 / 2009



[HUG#1365562]





    Company Announcement no 74 2009: 

http://hugin.info/2013/R/1365562/333522.pdf